Company intelligence / Profile preview

Novamind

Layton / Springville / Draper / Murray, Utah, United States

Ownership: Private
Development stage: Other

Overview

Novamind operates as a CRO and clinic network, hosting clinical trials in mental health—especially psychedelic medicine—and has delivered thousands of ketamine/esketamine treatments, hosted pivotal studies (e.g., Spravato), and acts as a research site for mid- and late-stage trials (e.g., BNC210 for PTSD, KarXT for schizophrenia)[2][3][7].

Therapeutic areas: OtherPsychiatry
Modalities: Small molecule (ketamine, esketamine, other psychedelic drugs)Device (nasal spray administration, e.g., Spravato)
Industry: Contract Research Organization

Partnerships

Merck & Co. (host of clinical trials)[3][7]Karuna Therapeutics (research site for KarXT study)[7]Bionomics (strategic investment; clinical trial site for BNC210)[2]Wholeness Center (Frontline KAP program)[3]

Beyond the preview

Go deeper on Novamind.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novamind.

Explore the full profile